Skip to main content
. 2018 Nov 14;4:37. doi: 10.1038/s41523-018-0090-6

Fig. 3.

Fig. 3

Kaplan–Meier estimates of the probability of remaining free of distant recurrence by TAILORx RS groups following exclusion of patients with presumed HER2-positive disease comparing treatment with tamoxifen alone with tamoxifen plus chemotherapy. a RS < 11; b RS 11–25; c RS > 25